Who Paid My Doc
Roozbeh Sharif
Pulmonary Disease Nederland, TX Medical Doctor
NPI 1396037008 CMS profile 688165
2300 Highway 365 Ste 150, Nederland, TX 77627
General payments
$22,813
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$1,418,634
Through program year 2025, Roozbeh Sharif of Nederland, TX is reported in the CMS Open Payments database as having received $22,813 across 325 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,418,634 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 90th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $9,202 | 104 | |
| 2024 | General | $2,920 | 116 | |
| 2023 | General | $6,570 | 66 | |
| 2022 | General | $3,080 | 33 | |
| 2021 | General | $1,040 | 6 |
Beside peers
- Roozbeh Sharif
- Pulmonary Disease median
- Middle half of Pulmonary Disease
- National median
In program year 2025, general payments to Roozbeh Sharif were reported at $9,202. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.
Show as a table
| Year | Roozbeh Sharif | Pulmonary Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $377 | $109–$1,340 | $163 |
| 2020 | $0 | $230 | $56–$907 | $114 |
| 2021 | $1,040 | $269 | $68–$1,072 | $132 |
| 2022 | $3,080 | $390 | $100–$1,457 | $149 |
| 2023 | $6,570 | $419 | $114–$1,659 | $160 |
| 2024 | $2,920 | $476 | $123–$1,818 | $164 |
| 2025 | $9,202 | $500 | $124–$1,893 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 54 drugsPart D claims
6,519
Drug cost
$8,027,202
Branded share of claims
61.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ofev Nintedanib Esylate | Brand | 177 | $2,268,460 | |
| Tyvaso Dpi Treprostinil | Brand | 65 | $1,609,021 | |
| Uptravi Selexipag | Brand | 36 | $941,959 | |
| Dupixent Pen Dupilumab | Brand | 216 | $873,447 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 1,058 | $743,268 | |
| Opsumit Macitentan | Brand | 58 | $711,267 | |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | Brand | 383 | $262,803 | |
| Tezspire Tezepelumab-Ekko | Brand | 24 | $100,138 | |
| Nucala Mepolizumab | Brand | 21 | $97,769 | |
| Xolair Omalizumab | Brand | 12 | $97,723 |
The 10 drugs with the highest cost, of 54 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 61 billing codesPaid by Medicare
$461,694
Medicare patients
378
Services billed
6,527
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| COPD | 75% | |
| Ischemic heart disease | 60% | |
| Arthritis | 54% | |
| Diabetes | 48% | |
| Heart failure | 46% | |
| Chronic kidney disease | 36% | |
| Atrial fibrillation | 34% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 38 | 48 | $17 |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme J7620 | Office | 51 | 54 | $8 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 45 | 60 | $6 |
| Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg J7614 | Office | 79 | 85 | $4 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 14 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| DUPIXENT |
|
$359 | 216 | — |
| FASENRA |
|
$149 | 13 | — |
| OPSUMIT |
|
$139 | 58 | — |
| UPTRAVI |
|
$139 | 36 | — |
| AIRSUPRA |
|
$110 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 14 in the dashboard with a free accountRecords
325 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pulmonary Disease in Texas
Antonio Anzueto
Pulmonary Disease · San Antonio, TX
Diego Maselli Caceres
Pulmonary Disease · San Antonio, TX
Nicola Hanania
Pulmonary Disease · Houston, TX
Juan Iribarren
Pulmonary Disease · Beaumont, TX
William Calhoun
Pulmonary Disease · Galveston, TX
David Marks
Pulmonary Disease · San Antonio, TX
Related records
Pulmonary Disease in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Pulmonary Disease
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.